Meeting Banner
Abstract #4850

Intrinsic susceptibility MRI can inform on tumour vascular decompression in response to the stromal targeted therapy PEGPH20

Emma L. Reeves1, Jin Li1, Jessica K. R. Boult1, Barbara Blouw2, David Kang2, Jeffrey C. Bamber1, Yann Jamin1, and Simon P. Robinson1
1Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom, 2Halozyme Therapeutics, San Diego, CA, United States

PEGPH20 has been shown to decompress blood vessels and improve tumour drug delivery. Given the sensitivity of R2* to paramagnetic deoxyhaemoglobin and reflection of RBC content in tumour vasculature, we hypothesised that IS-MRI may provide a useful biomarker of PEGPH20 response. We performed IS-MRI before and after PEGPH20 treatment in 4T1 HAS3 and MDA-MB-231 LM2-4 orthotopic breast tumours. R2* significantly increased following PEGPH20 treatment in 4T1 HAS3 tumours, however, R2* was unable to detect a similar response to PEGPH20 in the relatively hypovascular MDA-MB-231 LM2-4 tumours. Another vascular biomarker may provide greater sensitivity and detect PEGPH20 response in hypovascular tumours.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here